chronic heart failure
Conditions
Interventions
conventional treatment group:Heart failure (routine therapy including positive inotropic drugs, diuretics and vasodilator, angiotensin converting enzyme inhibitors, beta-blockers, phosphodiesterase in
phosphocreatine group:On the basis of routine therapy heart failure combined with creatine phosphate
Levosimendan group:On the basis of routine therapy heart failure combined with Levosimendan
Recombinant Human Brain Natriuretic Peptideon group:On the basis of routine therapy heart failure combined with Recombinant Human Brain Natriuretic Peptideon
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
40 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. cardiac insufficiency symptoms or signs; 2. heart function in line with the New York heart association class III-IV; 3. the hospital inpatients; 4. use our echocardiography, confirmed that the left ventricular ejection fraction (LVEF) of 40% or less; 5. all the subjects or his guardian consent form must be signed before entering the test subjects.
Exclusion criteria
Exclusion criteria: 1. acute myocardial infarction, or other causes of acute left heart failure; 2. with pure severe valvular stenosis (aortic and mitral valve), hypertrophic or restrictive cardiomyopathy; 3. serious ventricular arrhythmia; 4. the test drug allergy or taboo; 5. uncontrolled thyroid disease; 6. decubitus systolic blood pressure 180 mmHg; 7. liver and kidney function is not completed; 8. cardiac shock, blood volume is insufficient or cannot use vasodilator; 9. participated in other clinical researchers within three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Galectin-3;Copeptine;ST2;NT-prpBNP; | — |
Countries
China
Contacts
Public ContactXing Yanqiu
Outcome results
None listed